C4 Therapeutics (CCCC)
NASDAQ:CCCC
Want to see CCCC full AI Analyst Report?
CCCC Stock Chart & Stats
$2.92
-$0.05(-1.30%)
At close: 4:00 PM EST
$2.92
-$0.05(-1.30%)
Day’s Range― - ―
52-Week Range$1.21 - $3.95
Previous CloseN/A
Volume165.25K
Average Volume (3M)2.88M
Market Cap
$401.36M
Enterprise Value$229.72M
Total Cash (Recent Filing)$235.67M
Total Debt (Recent Filing)$58.45M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Aug 12, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.19
Shares Outstanding110,567,220
10 Day Avg. Volume4,147,757
30 Day Avg. Volume2,878,552
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)0.62
Price to Sales (P/S)4.40
P/FCF Ratio-1.59
Enterprise Value/Market Cap0.57
Enterprise Value/Revenue6.59
Enterprise Value/Gross Profit6.95
Enterprise Value/Ebitda-2.12
Forecast
1Y Price Target
$13.60Price Target Upside365.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.09
Revenue Forecast (FY)$21.62M
Bulls Say, Bears Say
Bulls Say
Strategic Roche CollaborationThe expanded Roche deal provides durable, non-dilutive funding and strategic validation: Roche leads development, manufacturing and commercialization while C4 supplies TORPEDO degraders and retains tiered royalties. This reduces execution and commercialization risk for partnered programs long-term.
Proprietary TORPEDO PlatformOwning a specialized discovery platform (TORPEDO) creates a durable competitive advantage by enabling repeatable degrader design across targets. Platform-led R&D supports multiple programs, fuels collaborations, and can scale into new modalities (e.g., DACs) with long-term IP and dealflow benefits.
High Gross Margin ProfileVery high gross margins reflect the licensing/collaboration revenue mix and indicate strong product economics once programs commercialize. High margins offer operating leverage potential: incremental revenue could flow to the operating line more quickly as R&D intensity normalizes or is shared with partners.
Bears Say
Sustained Cash BurnConsistent multi-year negative operating and free cash flow creates dependency on external funding or milestone receipts. Persistent burn elevates dilution and partnership risk, and forces management to prioritize near-term financing or milestone-driven programs rather than pure long-term portfolio breadth.
Deep Negative ProfitabilityExtremely negative net margins and large operating losses signal the company is far from self-sustaining. Negative profitability weakens returns on equity and increases reliance on funding rounds or partner milestones to continue development, raising execution and balance-sheet erosion risk over time.
Modest, Declining Revenue BaseA small and shrinking revenue base limits internal funding capacity and makes R&D spending a higher share of resources. Revenue volatility tied to milestone timing or collaboration schedules can delay self-funding, prolong cash burn, and constrain investment in broader pipeline advancement.
C4 Therapeutics News
CCCC FAQ
What was C4 Therapeutics’s price range in the past 12 months?
C4 Therapeutics lowest stock price was $1.21 and its highest was $3.95 in the past 12 months.
What is C4 Therapeutics’s market cap?
C4 Therapeutics’s market cap is $401.36M.
When is C4 Therapeutics’s upcoming earnings report date?
C4 Therapeutics’s upcoming earnings report date is Aug 12, 2026 which is in 89 days.
How were C4 Therapeutics’s earnings last quarter?
C4 Therapeutics released its earnings results on May 12, 2026. The company reported -$0.2 earnings per share for the quarter, beating the consensus estimate of -$0.251 by $0.051.
Is C4 Therapeutics overvalued?
According to Wall Street analysts C4 Therapeutics’s price is currently Undervalued.
Does C4 Therapeutics pay dividends?
C4 Therapeutics does not currently pay dividends.
What is C4 Therapeutics’s EPS estimate?
C4 Therapeutics’s EPS estimate is -0.22.
How many shares outstanding does C4 Therapeutics have?
C4 Therapeutics has 110,567,220 shares outstanding.
What happened to C4 Therapeutics’s price movement after its last earnings report?
C4 Therapeutics reported an EPS of -$0.2 in its last earnings report, beating expectations of -$0.251. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of C4 Therapeutics?
Currently, no hedge funds are holding shares in CCCC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
C4 Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.60 (365.75% Upside)
$13.60 (365.75% Upside)
Blogger Sentiment
Bullish
CCCC Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 8.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.9%
Last 30 Days ▲ 13.0%
Last 30 Days ▲ 13.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
133.60%
12-Months-Change
Fundamentals
Return on Equity
-53.83%
Trailing 12-Months
Asset Growth
2.92%
Trailing 12-Months
Company Description
C4 Therapeutics
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
CCCC Stock 12 Month Forecast
Average Price Target
$13.60
▲(365.75% Upside)
Technical Analysis
SELLAS Life Sciences Group
―
Seres Therapeutics
―
Eledon Pharmaceuticals
―
Tevogen Bio Holdings
―
Actuate Therapeutics, Inc.
―
Ownership Overview
2.97% Insiders
8.43% Mutual Funds
16.01% Other Institutional Investors
66.79% Public Companies and
Individual Investors